A phase II study of PS341 alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction (GEJ) or stomach

Trial Profile

A phase II study of PS341 alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction (GEJ) or stomach

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2014

At a glance

  • Drugs Bortezomib (Primary) ; Irinotecan
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jun 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.
    • 16 Nov 2006 Status change
    • 31 Oct 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top